The collaborative team, led by Dr. Rebecca Powell, Assistant Professor of Medicine (Infectious Diseases), secured an NIH R01 Emergency Award of USD 2m dollars to expand this study.
To date, preliminary in vitro studies demonstrate full neutralization of SARS-CoV-2 viral components, emphasizing the potential applicability of LCTG-001 to COVID-19 infections.
Lactiga has engaged the United States Food and Drug Administration through the Coronavirus Treatment Acceleration Program to optimize its transition from research toward first-in-human clinical testing.
With over 7.8m cases and 210,000 deaths in the US alone, a novel therapeutic that reduces COVID morbidity rates is critical.
Lactiga is a biotechnology company developing new treatment options for patients with Primary Immunodeficiency Diseases including Selective IgA Deficiency, Common Variable Immunodeficiency and other rare immune diseases, and repurposing its technology toward COVID-19 treatment in response to the global pandemic.
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region.
Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases.
The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island.
The Mount Sinai Hospital is ranked No. 14 on US News and World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in the country.
Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by US News and World Report.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial